source
- FDA again turns back Capricor Duchenne cell therapyIn an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.BioPharma Dive · 1h ago↗ source
- Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapyCompass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…